(Q38157342)

29 August 2017

title

Management of gastric cancer in Asia: resource-stratified guidelines (English)

1 reference

29 August 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Kun-Huei Yeh

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Lin Shen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Yan-Shen Shan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Huang-Ming Hu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Bhawna Sirohi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Yi-Hsin Yang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Takeshi Sano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Han-Kwang Yang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Xiaotian Zhang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Sook Ryun Park

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Masashi Fujii

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Yoon-Koo Kang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Li-Tzong Chen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

1 November 2013

1 reference

Lancet Oncology Commission

29 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

e535-47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

Japanese gastric cancer treatment guidelines 2010 (ver. 3).

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Screening for gastric cancer in Asia: current evidence and practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Asia-Pacific consensus guidelines on gastric cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

A new approach for elimination of gastric cancer deaths in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Magnifying Narrowband Imaging Is More Accurate Than Conventional White-Light Imaging in Diagnosis of Gastric Mucosal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

7th edition of the AJCC cancer staging manual: stomach.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Comparison of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Imaging in local staging of gastric cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Longterm outcomes after endoscopic mucosal resection for early gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Nodal dissection for patients with gastric cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Meta-analysis of laparoscopy-assisted and open distal gastrectomy for gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrectomy with open distal gastrectomy for gastric adenocarcinoma (KLASS 01).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric Cancer (JCOG0912)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970436-4

7 January 2021

10.1016/S1470-2045(13)70436-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24176572%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference